Fungal keratitis.

PURPOSE OF REVIEW

Throughout the world, fungal keratitis is a leading cause of ocular morbidity. The purpose of this review is to discuss the recently published literature in relation to the epidemiology, etiology, diagnosis, and therapy of fungal keratitis.

RECENT FINDINGS

Globally, the incidence of keratomycoses and systemic mycoses is rising. Current therapies are often ineffective. Ongoing research toward rapid diagnosis and specific drug therapy could minimize the morbidity caused by this preventable disease. New antifungal drugs, including voriconazole, have been applied recently for the treatment of keratomycosis.

SUMMARY

The incidence of fungal keratitis is on the rise in the densely populated continents of Asia and Africa. Filamentous fungi are the most frequently reported pathogens. Polyene antifungal antibiotics, the first-line therapy in fungal keratitis, are not effective in severe keratomycosis. Imidazole derivatives such as voriconazole and echinocandin may be the better choice in the future.